Workit Labs, the research division of Workit Health, a leading provider of virtual substance use disorder treatment, announced the publication of a study in the journal Telemedicine and E-Health. This study represents the most extensive sample to date of American patients residing in rural areas who have received telemedicine treatment for opioid use disorder. The findings demonstrate that telemedicine is a highly effective solution for rural populations grappling with opioid use disorder, effectively addressing the challenges of accessibility and treatment retention.
The peer-reviewed study, titled "Retention in Telehealth Treatment for Opioid Use Disorder Among Rural Populations: A Retrospective Cohort Study," underscores the success of telemedicine in delivering opioid use disorder treatment to individuals living in rural communities.
The study encompassed a cohort of over 1,800 rural patients from 14 states across the United States, providing a comprehensive view of the impact of telemedicine on opioid use disorder treatment outcomes. The patients had an average age of 37 years, and nearly two-thirds of them were insured by Medicaid. The findings revealed remarkable retention rates among patients engaged in telemedicine-delivered treatment, surpassing or aligning with retention rates reported in traditional in-person settings. Notably, over half of the patients remained in care at the six-month mark, an improvement from previous studies that relied on claims and discharge data for in-person treatment, which reported retention rates ranging from 35% to 41%.
The study also shed light on the high adherence to buprenorphine treatment within the telemedicine-delivered model. An impressive 90% of retained patients completed urine drug screens at each time point, and among those who participated, an overwhelming 99% displayed positive results for buprenorphine. These findings underscore the robust adherence to buprenorphine treatment among patients receiving telemedicine-delivered care, alleviating concerns regarding diversion and reinforcing the efficacy and integrity of this treatment approach.
The results of this study not only demonstrate the effectiveness of telemedicine in retaining patients and improving treatment outcomes in rural areas but also highlight the positive impact of telemedicine on buprenorphine adherence, mitigating potential concerns surrounding diversion. By embracing telemedicine as a powerful tool for delivering evidence-based care, Workit Health continues to lead the way in pioneering innovative solutions that ensure equal access to comprehensive addiction treatment, benefiting individuals and communities nationwide.
Workit Health's telemedicine-delivered treatment platform combines evidence-based practices with convenient, virtual care, allowing patients to access comprehensive addiction treatment from the comfort of their homes. The study's findings support the growing body of research that demonstrates the effectiveness of telemedicine in expanding treatment access and improving patient outcomes.
Click here to read the original news story.